| baxdrostat (CIN-107) / AstraZeneca |
Bax24, NCT06168409: A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension |
|
|
| Recruiting | 3 | 212 | Europe, Canada, US, RoW | Baxdrostat, CIN-107, Placebo | AstraZeneca | Resistant Hypertension | 09/25 | 09/25 | | |
NCT06268873: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. |
|
|
| Recruiting | 3 | 2500 | Europe, Canada, Japan, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat CIN-107, Dapagliflozin in combination with placebo | AstraZeneca | Chronic Kidney Disease and Hypertension | 12/27 | 12/27 | | |
BaxAsia, NCT06344104: A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension |
|
|
| Recruiting | 3 | 300 | Japan, RoW | Baxdrostat, CIN-107, Placebo | AstraZeneca | Uncontrolled Hypertension, Resistant Hypertension | 05/26 | 05/26 | | |
BaxDuo-Pacific, NCT06742723: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure |
|
|
| Not yet recruiting | 3 | 5000 | Europe, Canada, Japan, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat CIN-107, Placebo/dapagliflozin | AstraZeneca | Chronic Kidney Disease and Hypertension | 04/30 | 04/30 | | |
Prevent-HF, NCT06677060: Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin |
|
|
| Not yet recruiting | 3 | 11300 | Europe, Canada, Japan, RoW | Baxdrostat and dapagliflozin, Baxdrostat CIN-107, Placebo and dapagliflozin | AstraZeneca | Heart Failure | 12/29 | 12/29 | | |
BaxHTN, NCT06034743: A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension |
|
|
| Recruiting | 3 | 720 | Europe, Canada, Japan, US, RoW | Baxdrostat, CIN-107, Placebo | AstraZeneca | Uncontrolled Hypertension, Resistant Hypertension | 06/25 | 10/25 | | |
NCT05459688: Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 |
|
|
| Completed | 2 | 175 | US | CIN-107 | AstraZeneca | Hypertension | 11/23 | 11/23 | | |
NCT05432167: A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease |
|
|
| Completed | 2 | 194 | US | CIN-107, Placebo | AstraZeneca, Parexel | Uncontrolled Hypertension, Chronic Kidney Diseases | 05/24 | 05/24 | | |
NCT06336356: A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension |
|
|
| Completed | 2 | 48 | US | Baxdrostat, RO6836191,, CIN-107, Placebo | AstraZeneca | Uncontrolled Hypertension | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 15 | US | CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing | AstraZeneca | Primary Aldosteronism, Hyperaldosteronism | 10/24 | 10/24 | | |
NCT05963009: Baxdrostat Bioavailability and Bioequivalence Study |
|
|
| Completed | 1 | 14 | US | baxdrostat (formerly CIN-107) oral solution, baxdrostat (formerly CIN-107) tablet | AstraZeneca | Hypertension | 04/20 | 04/20 | | |
NCT05961384: Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat |
|
|
| Completed | 1 | 8 | US | baxdrostat, CIN-107 | AstraZeneca | Hypertension | 01/22 | 01/22 | | |
NCT05961397: Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment |
|
|
| Completed | 1 | 20 | US | baxdrostat, CIN-107 | AstraZeneca | Hypertension | 04/22 | 04/22 | | |
NCT05966324: Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population |
|
|
| Completed | 1 | 41 | US | baxdrostat, CIN-107 | AstraZeneca | Hypertension | 09/22 | 09/22 | | |
NCT06194032: A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants |
|
|
| Completed | 1 | 28 | Europe | Baxdrostat, Placebo, Moxifloxacin | AstraZeneca | Healthy Participants | 05/24 | 05/24 | | |
NCT06357520: A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants |
|
|
| Completed | 1 | 14 | US | Baxdrostat, CIN-107, Itraconazole | AstraZeneca | Healthy Participants | 06/24 | 06/24 | | |
NCT06657105: A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential |
|
|
| Active, not recruiting | 1 | 22 | US | EE/LNG, Baxdrostat | AstraZeneca | Healthy Participants | 02/25 | 02/25 | | |
